Aurobindo gets FDA nod for generic Trilipix
Aurobindo has received the Food and Drug Administration’s blessing for fenofibric acid delayed-release capsules in dosage strengths of 45 mg and 135 mg.
The product is the generic of Abbvie’s Trilipix.
It is used to treat cholesterol in the blood by lowering the total amount of triglycerides and LDL cholesterol and increasing the HDL cholesterol. It also is used along with diet to lower severely high triglycerides. Trilipix should only be used when other measures, such as diet and exercise, have not been enough.
Fenofibric acid delayed-release capsules have a market value of roughly $42 million for the 12 months ended in June, according to IQVIA.
The product is the generic of Abbvie’s Trilipix.
It is used to treat cholesterol in the blood by lowering the total amount of triglycerides and LDL cholesterol and increasing the HDL cholesterol. It also is used along with diet to lower severely high triglycerides. Trilipix should only be used when other measures, such as diet and exercise, have not been enough.
Fenofibric acid delayed-release capsules have a market value of roughly $42 million for the 12 months ended in June, according to IQVIA.